Sakar Healthcare Stock Surges 350% in 5 Years on Strong Profit Growth
Source: Mint Markets
Arth Insight · What this means for your wallet
- A 350% return turns a ₹1 lakh investment into ₹4.5 lakh, highlighting the wealth-building power of long-term equity holding.
- The 120% profit jump suggests strong business health, which often leads to higher dividends or further stock price appreciation.
- Rapid surges can lead to high 'Price-to-Earnings' ratios, meaning new investors might pay a premium price for future growth.
Wealth-Impact Simulator
See what a one-time investment could grow to.
Indicative estimate for education only — not investment advice.
Explore investmentsSakar Healthcare's share price saw a significant jump, trading at ₹817.45 today, following a 120% year-on-year rise in net profit for Q1 FY27. The stock has delivered a remarkable 350% return over the past five years.
- ▸Sakar Healthcare stock is trading higher after reporting a 120% profit jump in Q1 FY27.
- ▸The stock has delivered a 350% return over the last five years.
- ▸The company's strong financial performance has led to significant shareholder value creation.
- ✓Sakar Healthcare stock is trading higher after reporting a 120% profit jump in Q1 FY27.
- ✓The stock has delivered a 350% return over the last five years.
- ✓The company's strong financial performance has led to significant shareholder value creation.
Sakar Healthcare's stock opened at ₹817.45 today, up from its previous close of ₹802.20, reaching an intraday high of ₹833.90 on July 27. This surge follows the company's impressive financial results, which reported a 120% year-on-year increase in net profit for the first quarter of the fiscal year 2027 (Q1 FY27).
Over the last five years, Sakar Healthcare has demonstrated exceptional growth, with its share price rallying by approximately 350%. This sustained performance indicates strong investor confidence and robust operational execution by the company.
The company's financial performance in Q1 FY27 highlights its ability to significantly boost profitability. While specific figures for the net profit amount were not provided in the source material, the percentage increase suggests a substantial improvement in earnings.
Investors in Sakar Healthcare have benefited from this upward trend. The stock's consistent rally over half a decade points to its status as a multibagger, rewarding early investors with substantial returns. The recent profit jump is likely to further fuel interest in the stock.
This article is for informational purposes only and does not constitute investment advice.
Community Pulse · This story
How readers rate the outlook after reading this article. Anonymous · one vote per reader · updates live.
Some listings may be sponsored and Arth Vani may earn a referral fee. All information is for educational purposes only — verify terms and suitability with the provider before acting. Not financial advice.
Frequently Asked Questions
What is Sakar Healthcare's recent stock performance?
Sakar Healthcare's stock opened at ₹817.45 today, up from ₹802.20, and reached an intraday high of ₹833.90 on July 27. It has rallied 350% in five years.
Why has Sakar Healthcare's stock seen a surge?
The stock surge is attributed to the company reporting a 120% year-on-year rise in net profit for Q1 FY27.
What does a 'multibagger' stock mean?
A multibagger stock is one that provides returns of more than 100%, significantly multiplying the initial investment.
Join the Arth Vani channels
Daily news summaries, IPO & market alerts on Telegram and WhatsApp.
Because you read about Stock Market
Quadria Capital Plans Major Exits via Maxivision and Aragen IPOs by 2027
Healthcare-focused private equity firm Quadria Capital is targeting 1.5x cash returns for its investors by early 2027. The firm plans to achieve this through public listings of portfolio companies like Maxivision Eye Hospital and Aragen Life Sciences.
IPOBreakingCube Highways InvIT IPO: Allotment on July 29, Check Status Online
The allotment for Cube Highways Trust InvIT IPO, which was oversubscribed 9.35 times, is scheduled for July 29. Investors can check their share allotment status on the Kfin Technologies portal.
IPOChina Stocks Rebound as Memory Chipmaker CXMT Makes Blockbuster Market Debut
Chinese equity markets recovered on Monday as the successful listing of memory chipmaker CXMT Corp boosted investor sentiment. The surge in CXMT shares helped the CSI300 and Shanghai Composite indices gain ground following recent selloffs.
Related Stories
Quadria Capital Plans Major Exits via Maxivision and Aragen IPOs by 2027
Healthcare-focused private equity firm Quadria Capital is targeting 1.5x cash returns for its investors by early 2027. The firm plans to achieve this through public listings of portfolio companies like Maxivision Eye Hospital and Aragen Life Sciences.
IPOBreakingCube Highways InvIT IPO: Allotment on July 29, Check Status Online
The allotment for Cube Highways Trust InvIT IPO, which was oversubscribed 9.35 times, is scheduled for July 29. Investors can check their share allotment status on the Kfin Technologies portal.
IPOChina Stocks Rebound as Memory Chipmaker CXMT Makes Blockbuster Market Debut
Chinese equity markets recovered on Monday as the successful listing of memory chipmaker CXMT Corp boosted investor sentiment. The surge in CXMT shares helped the CSI300 and Shanghai Composite indices gain ground following recent selloffs.
IPOCXMT Shares Surge 500% in Shanghai Debut After Asia’s Largest IPO
Chinese chipmaker CXMT Corp saw its stock price skyrocket by 500% on its first day of trading on the Shanghai Stock Exchange. The company’s market valuation has now reached 3.65 trillion yuan (approx. ₹42.5 lakh crore), overtaking major banks like ICBC.